FI112090B - Menetelmä, plasmidi ja mikro-organismi difteriatoksiinin tai sen kanssa ristireagoivan CRM-proteiinin tuottamiseksi - Google Patents

Menetelmä, plasmidi ja mikro-organismi difteriatoksiinin tai sen kanssa ristireagoivan CRM-proteiinin tuottamiseksi Download PDF

Info

Publication number
FI112090B
FI112090B FI941050A FI941050A FI112090B FI 112090 B FI112090 B FI 112090B FI 941050 A FI941050 A FI 941050A FI 941050 A FI941050 A FI 941050A FI 112090 B FI112090 B FI 112090B
Authority
FI
Finland
Prior art keywords
plasmid
diphtheria toxin
crm197
gene
protein
Prior art date
Application number
FI941050A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI941050A (fi
FI941050A0 (fi
Inventor
Benjamin J Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of FI941050A0 publication Critical patent/FI941050A0/fi
Publication of FI941050A publication Critical patent/FI941050A/fi
Application granted granted Critical
Publication of FI112090B publication Critical patent/FI112090B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI941050A 1993-03-05 1994-03-04 Menetelmä, plasmidi ja mikro-organismi difteriatoksiinin tai sen kanssa ristireagoivan CRM-proteiinin tuottamiseksi FI112090B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2728393A 1993-03-05 1993-03-05
US2728393 1993-03-05

Publications (3)

Publication Number Publication Date
FI941050A0 FI941050A0 (fi) 1994-03-04
FI941050A FI941050A (fi) 1994-09-06
FI112090B true FI112090B (fi) 2003-10-31

Family

ID=21836767

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941050A FI112090B (fi) 1993-03-05 1994-03-04 Menetelmä, plasmidi ja mikro-organismi difteriatoksiinin tai sen kanssa ristireagoivan CRM-proteiinin tuottamiseksi

Country Status (21)

Country Link
US (1) US5614382A (fr)
EP (1) EP0616034B1 (fr)
JP (1) JP4144813B2 (fr)
KR (1) KR100316004B1 (fr)
CN (1) CN1100757A (fr)
AT (1) ATE280235T1 (fr)
AU (1) AU686126B2 (fr)
BR (1) BR1100634A (fr)
CA (1) CA2116914C (fr)
CZ (1) CZ39394A3 (fr)
DE (1) DE69434079T2 (fr)
DK (1) DK0616034T3 (fr)
ES (1) ES2231770T3 (fr)
FI (1) FI112090B (fr)
HU (1) HUT71320A (fr)
IL (1) IL108822A (fr)
NO (1) NO313758B1 (fr)
NZ (1) NZ260027A (fr)
PT (1) PT616034E (fr)
SK (1) SK24094A3 (fr)
ZA (1) ZA941548B (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0830146B1 (fr) * 1995-04-14 2010-03-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Techniques de declenchement d'une tolerance immunitaire a l'aide d'immunotoxine
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
CA2283497A1 (fr) * 1997-03-05 1998-09-11 David M. Neville Nouveaux vecteurs et procedes d'expression utiles pour produire des proteines mutantes
ATE433998T1 (de) 1997-03-05 2009-07-15 Us Health Divalent anti-t-zellen immuntoxinen und deren verwendung
US6676943B1 (en) * 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
CN1086945C (zh) * 1997-06-03 2002-07-03 胡章英 白喉口服液
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
MY144231A (en) 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
SG182163A1 (en) 2003-12-17 2012-07-30 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
CN101460180B (zh) * 2006-05-31 2012-06-27 西尔维奥·布齐 与白喉毒素免疫相关的蛋白质分子的药物应用
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN101265288B (zh) * 2007-03-13 2012-03-21 齐鲁制药有限公司 Crm197突变体的纯化方法
CN102413838A (zh) 2009-04-30 2012-04-11 科勒制药集团有限公司 肺炎球菌疫苗及其用途
JP5395264B2 (ja) 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物
EP3461496B1 (fr) 2009-06-22 2023-08-23 Wyeth LLC Compositions et procédés d'élaboration de compositions immunogènes conjuguées à polysaccharides capsulaires de sérotypes 5 et 8 de staphylococcus aureus
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
AU2010201410B2 (en) * 2010-03-30 2015-04-30 Pelican Technology Holdings, Inc. High level expression of recombinant CRM197
WO2011126811A2 (fr) 2010-03-30 2011-10-13 Pfenex Inc. Expression de protéines de toxines recombinantes en forte quantité
EP3170508B1 (fr) 2010-06-04 2019-11-13 Wyeth LLC Formulations vaccinales
CA2800774A1 (fr) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Vaccin peptidique ige ch3
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
CA2809758C (fr) 2010-09-10 2021-07-13 Wyeth Llc Variants non-lipidiques des antigenes orf 2086 de neisseria meningitidis
CN105693865B (zh) 2011-06-01 2020-07-17 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (fr) 2012-03-09 2022-08-17 Pfizer Inc. Compositions de neisseria meningitidis et procédés associés
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2879272A1 (fr) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides et leurs utilisations
CN102766647A (zh) * 2012-07-25 2012-11-07 天津康希诺生物技术有限公司 在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌
MX363511B (es) 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
PT2935299T (pt) 2012-12-20 2019-11-19 Pfizer Processo de glicoconjugação
AU2014203977B2 (en) 2013-01-04 2016-11-17 Obi Pharma, Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104140972B (zh) * 2013-05-07 2018-01-23 上海惠盾生物技术有限公司 白喉毒素突变体crm197的制备方法
EP3038979B1 (fr) 2013-08-26 2019-04-17 Corning Incorporated Procédé de recuisson localisée d'un verre renforcé
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
PL3583947T3 (pl) 2014-01-21 2024-04-02 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
KR102157200B1 (ko) 2014-01-21 2020-09-21 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
AU2015208820B2 (en) 2014-01-21 2020-05-14 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2017510290A (ja) 2014-01-31 2017-04-13 フィナ バイオソリューションズ リミテッド ライアビリティ カンパニー Ｃｒｍ１９７および関連タンパク質の発現および精製
EP3104886B1 (fr) 2014-02-14 2018-10-17 Pfizer Inc Conjugués immunogènes de glycoprotéine
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10280409B2 (en) 2014-11-20 2019-05-07 Biological E Limited Codon optimized polynucleotide for high level expression of CRM197
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
RS61440B1 (sr) 2015-06-23 2021-03-31 Biological E Ltd Multivalentna pneumokokna konjugatna vakcina
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
CA3005524C (fr) 2015-11-20 2023-10-10 Pfizer Inc. Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
CN118599011A (zh) 2016-03-10 2024-09-06 约翰·霍普金斯大学 产生不含聚集物的单体白喉毒素融合蛋白的方法和治疗用途
EP3269385A1 (fr) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugués de polysaccharide-protéine pneumococcique
WO2017220753A1 (fr) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugué polysaccharide pneumococcique-protéine
CA3031797A1 (fr) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Composition d'un conjugue polysaccharide-proteine pneumococcique multivalent
TWI789357B (zh) 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
BR112019006278A2 (pt) 2016-09-30 2019-07-02 Biological E Ltd composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.
WO2018144438A1 (fr) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Procédés de production de conjugués protéine-polysaccharide capsulaire à partir du sérotype 19f de streptococcus pneumoniae
KR101908590B1 (ko) 2017-02-01 2018-10-16 (주)포바이오코리아 Crm197의 용해성 단백질 발현 및 정제 방법
CA3052621A1 (fr) 2017-02-03 2018-08-09 Schadeck, Eva Barbara Compositions de conjugue saccharide d'haemophilus influenzae-excipient et leurs utilisations
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
UA127497C2 (uk) * 2017-04-22 2023-09-13 Байолоджикал Е Лімітед СПОСІБ ВЕЛИКОМАСШТАБНОГО ВИРОБНИЦТВА CRM<sub>197</sub>
KR20200051004A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
CN111683678B (zh) 2017-12-06 2024-01-26 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
KR102475419B1 (ko) * 2018-07-16 2022-12-07 주식회사 유바이오로직스 Crm197을 고농도로 발현하는 코리네박테리움 균주
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2021003358A (es) 2018-09-23 2021-05-27 Biological E Ltd Polisacaridos capsulares purificados de streptococcus pneumoniae.
CN109100517A (zh) * 2018-10-08 2018-12-28 武汉生命科技股份有限公司 一种用于检测白喉抗体的抗原蛋白、试剂盒及制备方法
CA3120922A1 (fr) 2018-12-12 2020-06-18 Pfizer Inc. Conjugues polysaccharide-proteine immunogenes a heteroantigenes multiples et leurs utilisations
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4003410A1 (fr) 2019-07-31 2022-06-01 Sanofi Pasteur, Inc. Compositions de conjugués de polysaccharide-protéine pneumococcique multivalents leurs méthodes d'utilisation
EP4051696A1 (fr) 2019-11-01 2022-09-07 Pfizer Inc. Compositions d'escherichia coli et méthodes associées
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
CA3173729A1 (fr) 2020-02-23 2021-08-26 Pfizer Inc. Compositions d'escherichia coli et methodes associees
EP3900739A1 (fr) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
EP3919076A1 (fr) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
WO2022043855A1 (fr) 2020-08-26 2022-03-03 Pfizer Inc. Conjugués polysaccharide-protéine de streptococcus du groupe b, procédés de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
CA3199094A1 (fr) 2020-10-22 2022-04-28 Pfizer Inc. Procedes de purification de polysaccharides bacteriens
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
EP4243863A2 (fr) 2020-11-10 2023-09-20 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
KR20220102871A (ko) 2021-01-14 2022-07-21 (주)셀트리온 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (fr) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination contre des infections à pneumocoque et à covid-19
EP4333879A1 (fr) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination contre des infections bactériennes et à betacoronavirus
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
EP4346893A2 (fr) 2021-05-28 2024-04-10 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
CN118510548A (zh) 2022-01-13 2024-08-16 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
WO2023218322A1 (fr) 2022-05-11 2023-11-16 Pfizer Inc. Procédé de production de formulations de vaccin avec des conservateurs
WO2024084397A1 (fr) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination contre infections à pneumocoques et à covid-19
WO2024089001A1 (fr) 2022-10-24 2024-05-02 Idorsia Pharmaceuticals Ltd Vaccin contre klebsiella pneumoniae
WO2024110827A1 (fr) 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024110839A2 (fr) 2022-11-22 2024-05-30 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué
WO2024121280A1 (fr) 2022-12-08 2024-06-13 Idorsia Pharmaceuticals Ltd Vaccin contre klebsiella pneumoniae
WO2024166008A1 (fr) 2023-02-10 2024-08-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024201324A2 (fr) 2023-03-30 2024-10-03 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH660375A5 (it) * 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
FR2549855B1 (fr) * 1983-07-29 1987-03-27 Grp Genie Genetique Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues

Also Published As

Publication number Publication date
FI941050A (fi) 1994-09-06
BR1100634A (pt) 1999-12-07
KR940021731A (ko) 1994-10-19
KR100316004B1 (ko) 2002-02-19
PT616034E (pt) 2005-02-28
JPH06292593A (ja) 1994-10-21
FI941050A0 (fi) 1994-03-04
IL108822A (en) 2004-09-27
SK24094A3 (en) 1995-03-08
JP4144813B2 (ja) 2008-09-03
DE69434079T2 (de) 2005-02-24
HUT71320A (en) 1995-11-28
CN1100757A (zh) 1995-03-29
DE69434079D1 (de) 2004-11-25
US5614382A (en) 1997-03-25
ZA941548B (en) 1994-10-03
DK0616034T3 (da) 2005-02-21
IL108822A0 (en) 1994-06-24
CA2116914C (fr) 2005-02-08
AU686126B2 (en) 1998-02-05
AU5759594A (en) 1994-09-08
CZ39394A3 (en) 1995-02-15
NO940774D0 (no) 1994-03-04
EP0616034A3 (en) 1996-10-16
CA2116914A1 (fr) 1994-09-06
EP0616034A2 (fr) 1994-09-21
NO313758B1 (no) 2002-11-25
NO940774L (no) 1994-09-06
NZ260027A (en) 1996-03-26
ES2231770T3 (es) 2005-05-16
ATE280235T1 (de) 2004-11-15
EP0616034B1 (fr) 2004-10-20
HU9400657D0 (en) 1994-05-30

Similar Documents

Publication Publication Date Title
FI112090B (fi) Menetelmä, plasmidi ja mikro-organismi difteriatoksiinin tai sen kanssa ristireagoivan CRM-proteiinin tuottamiseksi
FI101632B (fi) Menetelmä Bordetella pertussis-toksiinin alayksikön analogien valmista miseksi ja niitä koodaavia rekombinantti-DNA-molekyylejä
Logan et al. Evidence for posttranslational modification and gene duplication of Campylobacter flagellin
JPH08503602A (ja) 弱毒化細菌における組換え融合タンパク質の発現
JPS58126789A (ja) レースレオニンの製造法
EP0544685A1 (fr) Vecteurs
US8147841B2 (en) Clostridium toxin, and process for the preparation of immunogenic composition
AU743165B2 (en) Live attenuated bacteria of the species Actinobacillus pleuropneumoniae
CA3091583A1 (fr) Expression de proteine de surface pneumococcique a (pspa)
EP0742829B1 (fr) Expression de proteines heterologues dans des bacteries attenuees au moyen de promoteurs du gene htra
US7144576B1 (en) Modified pertussis toxin
AU2002301780B2 (en) Clostridium toxin and method for preparing immunogenic compositions
AU623867C (en) Recombinant DNA-derived bordetella toxin subunit analogs
AU2007201975B2 (en) Clostridium Toxin and Method for Preparing Immunogenic Compositions
EA045199B1 (ru) ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)

Legal Events

Date Code Title Description
MA Patent expired